Criteria of response was never going to be attainable in these late stage patients the anti leukaemia responses are what shows the possible advantage of treating patients who are not at such a late stage. You never pointed that sentence out or the blast count reduction, you cherry picked the results to back up your negatively exaggerated analysis. You are shameless. Imo
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-162
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.002(2.04%) |
Mkt cap ! $41.73M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.5¢ | 9.9¢ | $49.15K | 486.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 65751 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 226460 | 3 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| SPL (ASX) Chart |